These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11225688)

  • 1. Fluvoxamine for psychosis in Alzheimer's disease.
    Levkovitz Y; Bloch Y; Kaplan D; Diskin A; Abramovitchi I
    J Nerv Ment Dis; 2001 Feb; 189(2):126-9. PubMed ID: 11225688
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations.
    Baumann P; Eap CB; Zullino DF
    J Nerv Ment Dis; 2001 Nov; 189(11):798-9. PubMed ID: 11758666
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
    Pollock BG; Mulsant BH; Rosen J; Sweet RA; Mazumdar S; Bharucha A; Marin R; Jacob NJ; Huber KA; Kastango KB; Chew ML
    Am J Psychiatry; 2002 Mar; 159(3):460-5. PubMed ID: 11870012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 5. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    Hirose S; Ashby CR
    J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
    Stein MB; Fyer AJ; Davidson JR; Pollack MH; Wiita B
    Am J Psychiatry; 1999 May; 156(5):756-60. PubMed ID: 10327910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports.
    Chong SA; Tan CH; Lee HS
    J Clin Psychopharmacol; 1997 Feb; 17(1):68-9. PubMed ID: 9004072
    [No Abstract]   [Full Text] [Related]  

  • 10. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative symptoms of schizophrenia are improved by paroxetine added to neuroleptics: a pilot study.
    Jockers-Scherübl M; Godemann F; Pietzcker A
    J Clin Psychiatry; 2001 Jul; 62(7):573. PubMed ID: 11488373
    [No Abstract]   [Full Text] [Related]  

  • 12. Deliberate self-poisoning following fluvoxamine-neuroleptics combination.
    Chong SA; Cheong A
    J Clin Psychiatry; 1999 Dec; 60(12):869. PubMed ID: 10665638
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
    Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
    J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks.
    Albert R; Ebert D
    J Clin Psychiatry; 1996 Apr; 57(4):176. PubMed ID: 8601556
    [No Abstract]   [Full Text] [Related]  

  • 15. High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis.
    Leising J; Barr AM; Procyshyn RM; Ainsworth NJ; White RF; Honer W; Vila-Rodriguez F
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):186-190. PubMed ID: 33587389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
    Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
    Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexistent hypothyroidism, psychosis, and severe obsessions in an adolescent: a 10-year follow-up.
    Bhatara V; Alshari MG; Warhol P; McMillin JM; Bhatara A
    J Child Adolesc Psychopharmacol; 2004; 14(2):315-23. PubMed ID: 15319028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding other antipsychotics to clozapine.
    Cooke C; de Leon J
    J Clin Psychiatry; 1999 Oct; 60(10):710. PubMed ID: 10549694
    [No Abstract]   [Full Text] [Related]  

  • 19. [Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics?].
    Kurz A
    MMW Fortschr Med; 2006 Nov; 148(47):16. PubMed ID: 17168181
    [No Abstract]   [Full Text] [Related]  

  • 20. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.
    Arango C; Kirkpatrick B; Buchanan RW
    J Nerv Ment Dis; 2000 Jan; 188(1):50-3. PubMed ID: 10665462
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.